Science at the Patients' Service

At the Sanofi Pharmaceutical Innovation Center, the biopharmaceutical company is now presenting its global immunology strategy, highlighting the role of innovative medicines and vaccines in the future of medicine. First unveiled at the 2024 Olympic and Paralympic Games in Paris, the Sanofi Science Lab will now be the only one in Central Europe to be open to the professional public in Hungary, alongside Marseille, Barcelona, Milan and Frankfurt, the company says in a press release.

Sanofi's priority is to open up new dimensions in immunology medicine, with a strong focus on accelerating R&D. At the opening of the internationally renowned Sanofi Science Lab exhibition, one of the leading companies in the field of immunology is giving a high priority to digital innovation to find breakthrough solutions for the treatment of chronic diseases. Artificial intelligence will also play an important role in accelerating development processes, supporting decision-making and increasing research efficiency. This could halve the time it takes from identifying a molecule to bringing a specific drug to market. 

"Chronic diseases, including immunological diseases, are a major challenge worldwide. Sanofi is committed to bringing breakthroughs to patients' lives through modern, AI-enabled research and development practices, and to delivering them to as many people as possible in a timely and effective manner. Our scientific advances can make a positive difference to millions of lives, whether it's for common diseases such as chronic obstructive pulmonary disease (COPD) or to protect against the RSV virus that threatens infants. Not only can we help improve the quality of life for individuals, we can also help relieve pressure on the health system," according to Anthony Aouad, Regional Director of Sanofi.

In addition to staff, the event was attended by a wide range of experts, including researchers, physicians and technology partners. "Having the exhibition in Budapest, among other European cities, is very important for us. It is a recognition of the pharmaceutical presence that Sanofi has in our country, built on a tradition of more than 110 years. Through our factories, commercial, business services and clinical research activities, we work every day to ensure that Hungarian patients have access to world-class therapies. We are delighted to be able to demonstrate the role of digitalization and AI in the development of medicines and medicine not only in theory but also through practical examples, thus making our commitment to cutting-edge technologies tangible," the CEO of Sanofi Hungary Dr. Anikó Deszk, said at the press conference opening the exhibition.

The French Ambassador to Hungary, Jonathan Lacote stressed that "France is the fifth largest foreign investor in Hungary, with more than EUR 5.15 billion invested and 544 French companies creating nearly 49,000 jobs, particularly in the pharmaceutical, automotive and food sectors. The Sanofi Science Lab exhibition in Budapest not only demonstrates the development of science and technology, but also the importance of French-Hungarian cooperation in the field of health innovation and research. The exhibition also proves that French companies are not only investing, but are actively shaping the future of Hungary."